Grant: Project Grant - PA: Nutrition, Metabolism and Diabetes
Research Institute of the McGill University Health Centre
$100,000.00
Effect of Canagliflozin on Peritoneal Function and Fibrosis in Patients on Peritoneal Dialysis: a proof-of-concept randomized crossover clinical trial (CAN-PD trial).
EF 2024-25
Résumé
Peritoneal dialysis is a lifesaving treatment carried out in patients who develop kidney failure. In this procedure, a cleansing fluid called dialysate is passed through a tube placed into a part of the abdomen, known as the peritoneal cavity. The dialysate absorbs waste products and water from blood vessels in the lining of the abdomen, called the peritoneum. Then the fluid is drawn back out of the body and discarded. A major problem with this technique is that in some patients the amount of fluid that is discarded out reduces over a period of time. This leads to accumulation of fluid in the body and to detrimental effects and is called ultrafiltration failure. This happens because of the damage caused to the peritoneum by glucose (sugar) that is present in the dialysate.
Canagliflozin blocks glucose channels present in our body. It has been found to reduce glucose uptake by the peritoneum, reduce peritoneal damage, and increase ultrafiltration in animals but has not been studied in humans. In our study, patients undergoing peritoneal dialysis will participate. In the first part of study, patients will either receive canagliflozin or placebo (inactive pill which looks exactly same as canagliflozin) once daily for 5 weeks. Then, patients who earlier received placebo will be given canagliflozin and vice versa for 5 weeks. A third group of patients will receive no treatment. We will assess the function of the peritoneum by measuring glucose in the dialysate at the beginning of the study and after each treatment phase. This study will thus help us understand whether canagliflozin will reduce glucose uptake from the dialysate.
In the second part of the study, two thirds of patients will receive canagliflozin for 4 more months while one third of patients will not receive any treatment. We will measure levels of various harmful substances in the dialysate at the beginning and at 6 months. This will help us understand whether canagliflozin can prevent peritoneal damage.
Programme
Project Grant - PA: Nutrition, Metabolism and Diabetes
Emplacement
Quebec, Canada
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
515681
Name
Mavrakanas Thomas
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Clinical
Prcname2
Randomized Controlled Trials 2
Projecttitle
Effect of Canagliflozin on Peritoneal Function and Fibrosis in Patients on Peritoneal Dialysis: a proof-of-concept randomized crossover clinical trial (CAN-PD trial).
Programtype2
Operating Grants
Orgnameinp2
Research Institute of the McGill University Health Centre
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - PA: Nutrition, Metabolism and Diabetes
Keyworddelim
Biomarkers; Canagliflozin; Peritoneal Dialysis; Peritoneal Equilibration Test; Peritoneal Fibrosis; Randomized Crossover Study; Ultrafiltration Failure
Abstract
Peritoneal dialysis is a lifesaving treatment carried out in patients who develop kidney failure. In this procedure, a cleansing fluid called dialysate is passed through a tube placed into a part of the abdomen, known as the peritoneal cavity. The dialysate absorbs waste products and water from blood vessels in the lining of the abdomen, called the peritoneum. Then the fluid is drawn back out of the body and discarded. A major problem with this technique is that in some patients the amount of fluid that is discarded out reduces over a period of time. This leads to accumulation of fluid in the body and to detrimental effects and is called ultrafiltration failure. This happens because of the damage caused to the peritoneum by glucose (sugar) that is present in the dialysate.
Canagliflozin blocks glucose channels present in our body. It has been found to reduce glucose uptake by the peritoneum, reduce peritoneal damage, and increase ultrafiltration in animals but has not been studied in humans. In our study, patients undergoing peritoneal dialysis will participate. In the first part of study, patients will either receive canagliflozin or placebo (inactive pill which looks exactly same as canagliflozin) once daily for 5 weeks. Then, patients who earlier received placebo will be given canagliflozin and vice versa for 5 weeks. A third group of patients will receive no treatment. We will assess the function of the peritoneum by measuring glucose in the dialysate at the beginning of the study and after each treatment phase. This study will thus help us understand whether canagliflozin will reduce glucose uptake from the dialysate.
In the second part of the study, two thirds of patients will receive canagliflozin for 4 more months while one third of patients will not receive any treatment. We will measure levels of various harmful substances in the dialysate at the beginning and at 6 months. This will help us understand whether canagliflozin can prevent peritoneal damage.
Competitiondate
202409
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mavrakanas, Thomas; Nadeau-Fredette, Annie-Claire; Nessim, Sharon J; Trinh, Emilie
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~